Sunitinib Oltipraz has been shown to inhibit the growth

2022-01-03

Oltipraz has been shown to inhibit the growth of HCC Sunitinib and is being evaluated in clinical trials as a potential anti-cancer drug for HCC (Mann et al., 2009; Piton et al., 2005; Yates and Kensler, 2007). The present observation that pre-treatment of tumorigenic liver cells with oltipraz cause